Lenti-MART-1(DMF5) CAR (scFv-28ζ, Melan-A)-VP (VP-CAR-LC333)

The ready-to-use lentiviral particles of Lenti-MART-1(DMF5) CAR (scFv-28ζ, Melan-A)-VP is packaged using 3rd generation of lentiviral packaging system, in which the gene of CAR will be driven by a CMV promotor. The target gene of scFv (Melan-A)-CD28-CD3ζ packaged in lentiviral particles could be used for high efficency tranduction of T cells and stably integrated expression.

Datasheet   Add to Cart


  • Type of Therapeutics
  • Chimeric Antigen Receptor
  • Target
  • MART-1(DMF5)
  • Expression Cassette
  • scFv (Melan-A)-CD28-CD3ζ
  • Clone
  • Melan-A
  • Promotor
  • EF1a
  • Packaging System
  • Lentivirus
  • Packaging Cell
  • 293T
  • Targeting Diseases
  • Metastatic melanoma


  • Introduction
  • Involved in melanosome biogenesis by ensuring the stability of GPR143. Plays a vital role in theexpression, stability, trafficking, and processing of melanocyte protein PMEL, which is critical to theformation of stage II melanosomes.
  • Alternative Names
  • MLANA; Melan-A; Antigen LB39-AA; Antigen SK29-AA; Melanoma Antigen Recognized By T-Cells 1; MART1; MART-1; Protein Melan-A; TCR; T cell receptor; transgenic TCR; antigen-specific T cell receptors; Engineering T-cell receptors; recombinant t cell receptors; specific t cell receptor; modified t cell receptor; retroviral vector; Melanoma

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry


45-1 Ramsey Road, Shirley, NY 11967, USA
Call us at:
USA: 1-631-381-2994
Europe: 44-207-097-1828
Fax: 1-631-207-8356

Online Inquiry

For any technical issues or products/services related questions, please leave your contacts as below, and our team will contact you at earliest convenience to let you know how we can be involved in your projects.

  • Verification code

Key Updates

Receive the latest news and insights to your inbox.